Do analysts prefer GRDX or VERI?

Veritone has a consensus price target of $6.13, suggesting a potential upside of 664.38%. Given Veritone's stronger consensus rating and higher probable upside, analysts plainly believe Veritone is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veritone 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend GRDX or SNCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synchronoss Technologies 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts recommend CMCM or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cheetah Mobile 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend GRDX or AEYE?

Audioeye has a consensus target price of $14.63, indicating a potential upside of 102.56%. Given Audioeye's stronger consensus rating and higher possible upside, analysts plainly believe Audioeye is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Audioeye 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts recommend REKR or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rekor Systems 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Entero Therapeutics (GRDX) Competitors

$4.04 -0.02 (-0.49%)

As of 03:59 PM Eastern

Compare

GRDX vs. VERI, SNCR, CMCM, AEYE, and REKR

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include Veritone (VERI), Synchronoss Technologies (SNCR), Cheetah Mobile (CMCM), Audioeye (AEYE), and Rekor Systems (REKR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to Veritone?

Entero Therapeutics (NASDAQ:GRDX) and Veritone (NASDAQ:VERI) are both small-cap technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Entero Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market. Comparatively, Veritone has a beta of 2.29, suggesting that its share price is 129% more volatile than the broader market.

In the previous week, Veritone had 4 more articles in the media than Entero Therapeutics. MarketBeat recorded 7 mentions for Veritone and 3 mentions for Entero Therapeutics. Veritone's average media sentiment score of 1.10 beat Entero Therapeutics' score of 0.75 indicating that Veritone is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Veritone	Positive

Entero Therapeutics has higher earnings, but lower revenue than Veritone. Entero Therapeutics is trading at a lower price-to-earnings ratio than Veritone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	720.13	-$6.39M	-$1.88	N/A
Veritone	$92.19M	0.87	-$111.73M	-$0.38	N/A

Entero Therapeutics has a net margin of 0.00% compared to Veritone's net margin of -111.90%. Entero Therapeutics' return on equity of -47.34% beat Veritone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Veritone	-111.90%	-159.15%	-39.63%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 39.2% of Veritone shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 7.4% of Veritone shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Veritone has a consensus price target of $6.13, suggesting a potential upside of 664.38%. Given Veritone's stronger consensus rating and higher probable upside, analysts plainly believe Veritone is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veritone	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Veritone beats Entero Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to Synchronoss Technologies?

Entero Therapeutics (NASDAQ:GRDX) and Synchronoss Technologies (NASDAQ:SNCR) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Entero Therapeutics had 3 more articles in the media than Synchronoss Technologies. MarketBeat recorded 3 mentions for Entero Therapeutics and 0 mentions for Synchronoss Technologies. Entero Therapeutics' average media sentiment score of 0.75 beat Synchronoss Technologies' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Synchronoss Technologies	Neutral

Entero Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the broader market. Comparatively, Synchronoss Technologies has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Synchronoss Technologies has higher revenue and earnings than Entero Therapeutics. Synchronoss Technologies is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	720.13	-$6.39M	-$1.88	N/A
Synchronoss Technologies	$170.91M	0.61	$6.17M	-$1.02	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synchronoss Technologies	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Entero Therapeutics has a net margin of 0.00% compared to Synchronoss Technologies' net margin of -5.69%. Synchronoss Technologies' return on equity of 24.44% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Synchronoss Technologies	-5.69%	24.44%	3.59%

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Synchronoss Technologies shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Synchronoss Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Synchronoss Technologies beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Cheetah Mobile?

Cheetah Mobile (NYSE:CMCM) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Entero Therapeutics has a net margin of 0.00% compared to Cheetah Mobile's net margin of -21.14%. Cheetah Mobile's return on equity of -3.90% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cheetah Mobile	-21.14%	-3.90%	-1.50%
Entero Therapeutics	N/A	-47.34%	-16.07%

0.4% of Cheetah Mobile shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 17.1% of Cheetah Mobile shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Entero Therapeutics has lower revenue, but higher earnings than Cheetah Mobile. Cheetah Mobile is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cheetah Mobile	$164.51M	0.57	-$36.85M	-$1.17	N/A
Entero Therapeutics	$40K	720.13	-$6.39M	-$1.88	N/A

In the previous week, Entero Therapeutics had 3 more articles in the media than Cheetah Mobile. MarketBeat recorded 3 mentions for Entero Therapeutics and 0 mentions for Cheetah Mobile. Entero Therapeutics' average media sentiment score of 0.75 beat Cheetah Mobile's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cheetah Mobile	Neutral
Entero Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cheetah Mobile	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cheetah Mobile has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the broader market.

Summary

Entero Therapeutics beats Cheetah Mobile on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Audioeye?

Entero Therapeutics (NASDAQ:GRDX) and Audioeye (NASDAQ:AEYE) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Audioeye has higher revenue and earnings than Entero Therapeutics. Audioeye is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	720.13	-$6.39M	-$1.88	N/A
Audioeye	$40.31M	2.25	-$3.08M	-$0.36	N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 51.1% of Audioeye shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 25.9% of Audioeye shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has a net margin of 0.00% compared to Audioeye's net margin of -10.92%. Audioeye's return on equity of 121.59% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Audioeye	-10.92%	121.59%	15.45%

Entero Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Audioeye has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Audioeye has a consensus target price of $14.63, indicating a potential upside of 102.56%. Given Audioeye's stronger consensus rating and higher possible upside, analysts plainly believe Audioeye is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Audioeye	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Audioeye had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 4 mentions for Audioeye and 3 mentions for Entero Therapeutics. Audioeye's average media sentiment score of 0.96 beat Entero Therapeutics' score of 0.75 indicating that Audioeye is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Positive
Audioeye	Positive

Summary

Audioeye beats Entero Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Entero Therapeutics compare to Rekor Systems?

Rekor Systems (NASDAQ:REKR) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rekor Systems	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics has a net margin of 0.00% compared to Rekor Systems' net margin of -43.84%. Entero Therapeutics' return on equity of -47.34% beat Rekor Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rekor Systems	-43.84%	-59.05%	-27.37%
Entero Therapeutics	N/A	-47.34%	-16.07%

Entero Therapeutics has lower revenue, but higher earnings than Rekor Systems. Rekor Systems is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rekor Systems	$48.45M	1.63	-$31.46M	-$0.16	N/A
Entero Therapeutics	$40K	720.13	-$6.39M	-$1.88	N/A

45.7% of Rekor Systems shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 3.2% of Rekor Systems shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Rekor Systems had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for Rekor Systems and 3 mentions for Entero Therapeutics. Rekor Systems' average media sentiment score of 0.77 beat Entero Therapeutics' score of 0.75 indicating that Rekor Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Rekor Systems	Positive
Entero Therapeutics	Positive

Rekor Systems has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market.

Summary

Rekor Systems beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$28.81M	$15.68B	$29.12B	$12.77B
Dividend Yield	N/A	3.42%	2.75%	10.79%
P/E Ratio	-2.15	126.78	72.09	24.13
Price / Sales	720.13	1,303.50	595.79	98.17
Price / Cash	N/A	47.09	48.39	53.12
Price / Book	1.93	7.38	9.30	6.23
Net Income	-$6.39M	$434.52M	$676.02M	$348.07M
7 Day Performance	4.94%	2.33%	0.78%	0.66%
1 Month Performance	32.89%	6.61%	4.41%	4.84%
1 Year Performance	N/A	5.21%	188.36%	16.83%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	0.7265 of 5 stars	$4.04 -0.5%	N/A	N/A	$28.81M	$40K	N/A	9	Positive News Short Interest Increase High Trading Volume
VERI Veritone	3.0729 of 5 stars	$1.15 -22.8%	$6.13 +432.6%	-63.0%	$106.90M	$92.19M	N/A	550	Positive News Insider Trade High Trading Volume
SNCR Synchronoss Technologies	N/A	$9.00 flat	N/A	N/A	$103.56M	$170.91M	N/A	1,540
CMCM Cheetah Mobile	0.8559 of 5 stars	$3.33 +9.2%	N/A	-48.6%	$100.95M	$164.51M	N/A	850
AEYE Audioeye	3.9853 of 5 stars	$7.99 +37.5%	$14.63 +83.0%	-38.4%	$99.82M	$40.31M	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. VERI, SNCR, CMCM, AEYE, and REKR

How does Entero Therapeutics compare to Veritone?

Summary

How does Entero Therapeutics compare to Synchronoss Technologies?

Summary

How does Entero Therapeutics compare to Cheetah Mobile?

Summary

How does Entero Therapeutics compare to Audioeye?

Summary

How does Entero Therapeutics compare to Rekor Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. VERI, SNCR, CMCM, AEYE, and REKR

How does Entero Therapeutics compare to Veritone?

Which has more risk & volatility, GRDX or VERI?

Does the media favor GRDX or VERI?

Which has preferable valuation & earnings, GRDX or VERI?

Is GRDX or VERI more profitable?

Do institutionals & insiders hold more shares of GRDX or VERI?

Do analysts prefer GRDX or VERI?

Summary

How does Entero Therapeutics compare to Synchronoss Technologies?

Does the media favor GRDX or SNCR?

Which has more risk and volatility, GRDX or SNCR?

Which has better earnings & valuation, GRDX or SNCR?

Do analysts recommend GRDX or SNCR?

Is GRDX or SNCR more profitable?

Do institutionals & insiders believe in GRDX or SNCR?

Summary

How does Entero Therapeutics compare to Cheetah Mobile?

Is CMCM or GRDX more profitable?

Do insiders & institutionals hold more shares of CMCM or GRDX?

Which has preferable earnings and valuation, CMCM or GRDX?

Does the media prefer CMCM or GRDX?

Do analysts recommend CMCM or GRDX?

Which has more risk and volatility, CMCM or GRDX?

Summary

How does Entero Therapeutics compare to Audioeye?

Which has higher earnings & valuation, GRDX or AEYE?

Do institutionals and insiders believe in GRDX or AEYE?

Is GRDX or AEYE more profitable?

Which has more volatility and risk, GRDX or AEYE?

Do analysts recommend GRDX or AEYE?

Does the media refer more to GRDX or AEYE?

Summary

How does Entero Therapeutics compare to Rekor Systems?

Do analysts recommend REKR or GRDX?

Is REKR or GRDX more profitable?

Which has better valuation & earnings, REKR or GRDX?

Do institutionals & insiders hold more shares of REKR or GRDX?

Does the media prefer REKR or GRDX?

Which has more volatility & risk, REKR or GRDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools